Genome minimization ultimately leads to the smallest genome sustaining life of a given cell, however, growth of this cell may be very slow and may require multiple supplements e.g. to overcome amino acid auxotrophies. By contrast, genome reduction of industrially relevant bacteria such as Corynebacterium glutamicum does not aim at generating minimal cells. Rather chassis cells are developed that are as fit as the wild type with respect to a target function: for example growth of C. glutamicum in glucose minimal medium. Thus, a balance between reducing the burden of expressed genes while maintaining fast growth with glucose without the requirement for supplements such as amino acids is required. Here, the application of this concept to C. glutamicum is discussed. Moreover, an outlook on how the advent of genome editing by CRISPR-Cas9 or CRISPR-Cpf1 impacts genome reduction and how highly parallel genome editing must be met by highly parallel strain characterization is presented. Finally, metabolic engineering approaches for the overproduction of amino acids, organic acids, terpenoids and diamines making use of genome-reduced C. glutamicum strains are detailed.